About Mecrx pty ltd

About company

MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIRO and is headquartered in Melbourne, Australia. MecRx was founded in 2013 by an ex-pharma/biotech team. MecRx is run as a virtual company based in Melbourne, Australia and its shareholders and service providers include the Peter MacCallum Cancer Institute and CSIRO. The company secured $5m Series A investment from the MRCF (www.mrcf.com.au) and CSIRO in 2015.